(833) 317-6278
Book a Demo
Eleanor Laise
Gray shield icon
Is this you?
Claim your profile.

Eleanor Laise

AS SEEN ON
MarketWatch

Preston's Summary

Eleanor Laise is a reporter for MarketWatch, with her work also appearing in Yahoo Finance and BuradaBiliyorum. She covers a wide range of topics, including pharmaceutical companies, healthcare, biotechnology, and stock market analysis. Eleanor provides insightful reporting and analysis on the latest developments in these industries.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Cites Data: 32 %
Press Release: 29 %
Investment Analysis: 18 %
Private Sector Announcements: 7 %
Government Announcement: 7 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

Not enough data icon

Not enough data

Pitching Insights

Eleanor's coverage heavily focuses on the healthcare and pharmaceutical industries, particularly in relation to investment analysis and FDA approvals. Her articles often cite data or press releases.

Given her focus, Eleanor would likely welcome pitches from experts who can provide insightful commentary on pharmaceutical developments, investment trends within the healthcare sector, or the implications of FDA decisions on specific companies or industry sectors.

If you have expertise in biotechnology advancements, pharmaceutical market trends, stock analysis related to medical treatments or FDA approval processes, your insights may be valuable for Eleanor’s coverage.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Anjalee Khemlani

Anjalee Khemlani

Senior Health Reporter
*************ani@*************com
Publications
AOL, Inc.
Most recent topics
Not enough data
Eric Sagonowsky

Eric Sagonowsky

Senior Editor
*********ky@**************com
Publications
Fierce Pharma, Biotech
Most recent topics
Not enough data
Jennifer Calfas

Jennifer Calfas

Reporter
************fas@******m
Publications
LiveMint, The Wall Street Journal
Most recent topics
Not enough data
Dulan Lokuwithana

Dulan Lokuwithana

Editor - Breaking news (Healthcare)
****n@*************com
Publications
Seeking Alpha
Most recent topics
Not enough data
Zoey Becker

Zoey Becker

Staff Writer, Fierce Pharma
******r@*********om
Publications
Fierce Pharma, Biotech, NewsBreak
Most recent topics
Not enough data
David Wainer

David Wainer

Columnist
**********er@******m
Publications
The Wall Street Journal, Yahoo News
Most recent topics
Not enough data

Articles

MarketWatch

Pfizer's news of progress on obesity pill cheers investors

Pfizer's news of progress on obesity pill cheers investors

By: Eleanor Laise, Ciara Linnane

Pfizer Inc.’s stock rose 0.7% early Thursday, after the drug company said it has taken a step forward in developing a once-daily pill for obesity. The pharmaceutical giant said it has chosen a preferred modified-release formulation of its experimental drug danuglipron, which like Novo Nordisk’s Oze

© 2024 Intelligent Relations